Cedric Francois, Apellis CEO (Apellis)
March 17, 2021 05:00 PM EDTUpdated 05:21 PM
R&D

Lit­tle Apel­lis is arm­ing it­self for a David and Go­liath bat­tle over a block­buster drug fran­chise

John Carroll

Editor & Founder

Is a lit­tle biotech like Apel­lis $APLS ready for a David vs. Go­liath com­mer­cial bat­tle with a well-es­tab­lished phar­ma play­er and their fe­ro­cious Big Phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times